FDA-approved T-cell cancer therapy (a technology pioneered in Philadelphia), and name-brand research products. WuXi AppTec said the sale covered its U.S. and U.K. Advanced Therapies facilities.
Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925 million biobucks deal with WuXi Biologics for a preclinical candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback